企業プロフィール
Quest Diagnostics 株価・ニュース・カタリスト
- ティッカー:
- DGX
- 取引所:
- NYSE
- セクター:
- MedTech
- 所在地:
- Secaucus, New Jersey
株価パフォーマンス
235.52 USD (+0.48%)
終値
最終更新: 2026年8月17日
21.4B USD
時価総額
株価変動の要因
As of Aug 17, 2026, DGX closed up 0.48% at $235.52. No new same-company headline was identified in the current news window.
企業概要
Diagnostic Information Services Leader
Quest Diagnostics provides laboratory testing and diagnostic insights to physicians, hospitals, consumers, and population-health partners. Its core value lies in converting testing data into information that supports disease detection, treatment decisions, and health management.
Consumer Access Channels
Quest is expanding access through questhealth.com, consumer-health services, wearable-device partnerships, and wellness programs. These channels allow individuals and employers to use the company’s laboratory network outside traditional physician-ordered testing workflows.
Advanced Diagnostics
The Advanced Diagnostics portfolio includes blood-based Alzheimer’s testing and assays in cardiometabolic disease, endocrinology, and liver fibrosis. These higher-value tests extend Quest into areas requiring specialized interpretation and clinical decision support.
Oncology Testing and Digital Integration
Quest received New York State approval for the Haystack minimal residual disease test and is piloting molecular-testing integration through Flatiron Health’s OncoEMR Molecular Profiling Integration platform. These initiatives extend the company beyond traditional laboratory services into precision oncology and embedded clinical workflows.
National Laboratory Network
Quest’s scale is built on a broad network of laboratories, patient service centers, logistics, and relationships with physicians and health systems. This infrastructure supports high-volume routine testing while providing a distribution channel for newly introduced advanced diagnostics.
今後のカタリスト
- Quest Diagnostics should be watched for advanced-diagnostics mix, volume trends, and any acquisition or network-expansion step. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。